Go Back   HER2 Support Group Forums > her2group
Register Gallery FAQ Members List Calendar Search Today's Posts Mark Forums Read

Thread Tools Display Modes
Old 09-10-2019, 09:30 PM   #1
Senior Member
Join Date: Mar 2006
Posts: 4,778
Lasker award to Drs Slamon, Ullrich, Shepard


Lasker Awards Honor Seminal Advances in Immunology, Breast Cancer
Megan Brooks

September 10, 2019

The 2019 winners of the Lasker Awards were announced today. The awards honor seminal discoveries in immunology and breast cancer therapy.

Max D. Cooper, MD, of Emory University, Atlanta, Georgia, and Jacques Miller, MD, PhD, of the Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia, received the Albert Lasker Basic Medical Research Award for their discovery of the two distinct classes of lymphocytes, B and T cells.

Lasker Award winners for basic medical research Drs Max D. Cooper (l) and Jacques Miller (r).

This "monumental achievement...provided the organizing principle of the adaptive immune system and truly launched the course of modern immunology," Lasker Foundation President Claire Pomeroy, MD, said during a media briefing.

Sharing the Lasker-DeBakey Clinical Medical Research Award are H. Michael Shepard, PhD, formerly of Genentech, Dennis J. Slamon, MD, PhD, the University of California, Los Angeles, and Axel Ullrich, PhD, the Max Planck Institute of Biochemistry and formerly of Genentech, for developing trastuzumab, the first targeted therapy for HER2-positive breast cancer.

Lasker Award winners for clinical medical research (l-r) Drs H. Michael Shepard, Dennis J. Slamon, and Axel Ullrich.

"These researchers provided the first demonstration that monoclonal antibodies were a viable and effective strategy to treat solid tumors, opening a new path to develop and deploy antibodies to treat cancer," the Lasker Foundation said in a news release.

Basic Medical Research Award: Modern Immunology
Miller showed that the thymus, previously thought to be a useless organ, is essential for the development of immunity and immune function. Cooper then discovered that there are two distinct cell lineages in the adaptive immune system, B and T cells.

Working with chickens, Cooper found that the bursa of Fabricius, a sac-like lymphatic organ present only in birds, is the source of B cells in birds, and he characterized the different stages of B cell development.

Taking it a step further, Miller established that interactions between B and T cells are essential to their normal maturation and function. Cooper and colleagues later showed that, in mammals, B cells are generated in the liver of the fetus and, after birth, in bone marrow.

"These seminal discoveries defined the field of adaptive immunity and serve as the building blocks for current immunology research and clinical advances," the Lasker Foundation said in a news release.

"This pioneering work has fueled a tremendous number of advances in basic and medical science, several of which have received previous recognition by Lasker Awards and Nobel Prizes, including those associated with monoclonal antibodies, generation of antibody diversity, MHC restriction for immune defense, antigen processing by dendritic cells, and checkpoint inhibition therapy for cancer," the Lasker Foundation said.

Cooper and Miller are "like legends" because they made such a "foundational discovery," immunologist Marc Feldmann, PhD, FMedSci, professor emeritus, University of Oxford, United Kingdom, said in a YouTube video produced by the Lasker Foundation.

"Prior to their discovery, it was very clear that the immune system worked. But there was very little idea of how it worked. Jacques Miller and Max Cooper solved a very important puzzle that is progressively revolutionizing medicine. Their discoveries absolutely changed the world for the better," said Feldmann. (Feldmann shared the 2003 Lasker Award for Clinical Medical Research for the discovery of antitumor necrosis factor therapy as an effective treatment for rheumatoid arthritis and other autoimmune diseases.)

Lasker-DeBakey Award: First Targeted Breast Cancer Therapy
The combined efforts of Shepard, Slamon, and Ullrich led to the creation of trastuzumab, the first humanized monoclonal antibody that targets a protein encoded by an oncogene.

Ullrich found a gene, human epidermal growth factor receptor 2 gene (HER2), that makes a receptor that tells cells to grow and divide. Ullrich and Slamon then discovered that extra copies of the HER2 gene are present in 25% of breast cancers. For women with HER2+ breast cancer, disease-free and overall survival are shorter.

Working together, Ullrich, Slamon, and Shepard created an antibody that homed in on the HER2 receptor and suppressed growth of HER2+ breast cancer cells. In clinical trials, trastuzumab, when coupled with chemotherapy, stalled HER2+ breast cancer progression and extended survival compared to chemotherapy alone.

Trastuzumab is now standard therapy for HER2+ breast cancers. Every year, more than 50,000 women in the United States are diagnosed with HER2+ breast cancer, and more than 2.3 million have received the treatment since the US Food and Drug Administration approved it in 1998.

The Lasker Foundation notes that the impact of the development of trastuzumab goes beyond breast cancer by establishing that monoclonal antibodies can combat solid tumors. The innovation also offers a new model for personalized medicine by making available a diagnostic test that identifies the most appropriate patients to treat with a particular intervention.

"By uncovering and exploiting the molecular pathology of a devastating disease, Shepard, Slamon, and Ullrich conceived and executed a new blueprint for drug discovery that has already bestowed tens of thousands of women with time and quality of life," the Lasker Foundation said.

A YouTube video from the foundation traces the work of Shepard, Slamon and Ullrich.

The Lasker awards carry an honorarium of $250,000 for each category. They will be presented at a ceremony on September 20 in New York City.

Follow Medscape on Facebook, Twitter, Instagram, and YouTube

Medscape Medical News 2019

Cite this: Lasker Awards Honor Seminal Advances in Immunology, Breast Cancer - Medscape - Sep 10, 2019.
Lani is offline   Reply With Quote
Old 09-11-2019, 12:57 AM   #2
Senior Member
Pamelamary's Avatar
Join Date: Apr 2012
Location: Melbourne, Australia
Posts: 492
Re: Lasker award to Drs Slamon, Ullrich, Shepard

Nice to see a Melbournian among the luminaries.... Well deserved kudos for Slamon, though surely belated? Thanks Lani.
Pamelamary is offline   Reply With Quote
Old 09-27-2019, 12:55 AM   #3
Senior Member
Catherine's Avatar
Join Date: Dec 2006
Location: Oregon
Posts: 715
Re: Lasker award to Drs Slamon, Ullrich, Shepard

Thanks for posting, Lani. Lots of excellent science and discoveries. All of this research builds upon itself and we are so fortunate that the dedicated doctors and researchers continue on the mission to save lives. Hard work that benefits us all. And of course all of us with Her2 are thankful to Dr. Slamon for inventing Herceptin.

Found my own lump in the shower
April 2006 at the age of 58
Stage IIB, ER- PR- HER2+++ multi focal tumors, largest 2.3cm
Chemo first: AC/Taxol over 16 weeks
Bilateral mastectomy Sep 06
33 rads after the surgery
1 year of Herceptin completed Dec 07
15 years and no recurrence as of April 2021
Catherine is offline   Reply With Quote
Old 10-01-2019, 11:19 PM   #4
Senior Member
StephN's Avatar
Join Date: Nov 2004
Location: Misty woods of WA State
Posts: 4,128
Wink Re: Lasker award to Drs Slamon, Ullrich, Shepard

Great post with honors to our Herceptin researcher heros. I know I am still here because of their work. I will give them an award every hour of every day of my life.
"When I hear music, I fear no danger. I am invulnerable. I see no foe. I am related to the earliest times, and to the latest." H.D. Thoreau
Live in the moment.

Found suspicious lump 9/2000
Lumpectomy, then node dissection and port placement
Stage IIB, 8 pos nodes of 18, Grade 3, ER & PR -
Adriamycin 12 weekly, taxotere 4 rounds
36 rads - very little burning
3 mos after rads liver full of tumors, Stage IV Jan 2002, one spot on sternum
Weekly Taxol, Navelbine, Herceptin for 27 rounds to NED!
2003 & 2004 no active disease - 3 weekly Herceptin + Zometa
Jan 2005 two mets to brain - Gamma Knife on Jan 18
All clear until treated cerebellum spot showing activity on Jan 2006 brain MRI & brain PET
Brain surgery on Feb 9, 2006 - no cancer, 100% radiation necrosis - tumor was still dying
Continue as NED while on Herceptin & quarterly Zometa
Fall-2006 - off Zometa - watching one small brain spot (scar?)
2007 - spot/scar in brain stable - finished anticoagulation therapy for clot along my port-a-catheter - 3 angioplasties to unblock vena cava
2008 - Brain and body still NED! Port removed and scans in Dec.
Dec 2008 - stop Herceptin - Vaccine Trial at U of W begun in Oct. of 2011
STILL NED everywhere in Feb 2014 - on wing & prayer
7/14 - Started twice yearly Zometa for my bones
Jan. 2015 checkup still shows NED
2015 Neuropathy in feet - otherwise all OK - still NED.
Same news for 2016 and all of 2017.
Nov of 2017 - had small skin cancer removed from my face. Will have Zometa end of Jan. 2018.
StephN is offline   Reply With Quote

Thread Tools
Display Modes

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

BB code is On
Smilies are On
[IMG] code is On
HTML code is Off

Forum Jump

All times are GMT -7. The time now is 12:02 AM.

Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2022, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021
free webpage hit counter